Introduction {#s1}
============

Globally, cataract is one of the most serious blinding diseases [@pone.0033013-Resnikoff1]. Modern cataract surgery is routinely combined with the implantation of an intraocular lens (IOL). UV light-filtering lenses have been the dominant IOLs used in modern cataract surgery since the mid-1980 s because of the growing evidence that ultraviolet light caused photic retinopathy and cystoid macular edema [@pone.0033013-Ham1]. Recently there has been support for increasing the absorption spectrum of IOLs. The rationale is that UV light-filtering IOLs do not protect the retina from phototoxic damage by high-energy, short-wavelength blue light (approximately 400--480 nm) which is thought to contribute to the pathogenesis of age-related macular degeneration (AMD) [@pone.0033013-Tomany1], [@pone.0033013-Taylor1]. The healthy human crystalline lens gradually becomes yellow as part of the normal ageing process. This yellowing reduces the transmission of blue light, thereby blocking an amount of blue light from reaching the retina [@pone.0033013-vanNorren1]. After cataract extraction, the possibility of retinal exposure to blue light may accelerate AMD [@pone.0033013-Cugati1]. To address this potential damage, several blue light-filtering IOLs have been introduced in recent years. Their yellow tint more closely replicates the spectral transmission properties of the aged human crystalline lens than do the UV light-filtering IOLs [@pone.0033013-Brockmann1].

Despite the benefits of blue light filtering, concerns were raised that this could negatively affect visual performance after cataract surgery [@pone.0033013-Mainster1]. Specifically, controversy remains as to ultimate best corrected visual acuity (BCVA), contrast sensitivity, color vision and glare. In recent years, several studies were performed to test visual function with blue light-filtering IOLs. Some described a better [@pone.0033013-Niwa1]--[@pone.0033013-Yuan1] and others, a worse [@pone.0033013-Mainster1], [@pone.0033013-Schwiegerling1], [@pone.0033013-Pierre1], outcomes. However, we find that the majority of the literature did not describe any statistically significant differences in comparisons with UV light-filtering IOLs [@pone.0033013-Hayashi1]--[@pone.0033013-Marshall1], or, if present, these differences were most likely small.

In this paper, we conduct a systematic review and meta-analysis of published randomized controlled trials to assess the visual performance of blue light-filtering IOLs and UV light-filtering IOLs after cataract surgery.

Materials and Methods {#s2}
=====================

1. Search strategy {#s2a}
------------------

Two independent investigators (Zhu and Yu) searched publications from 2000 to June 30th, 2011 in PubMed, Embase, Cochrane Library, and the Chinese BioMedical Literature (CBM) databases by using the combination of MeSH terms "cataract extraction" or "phacoemulsification" or "lens" or "intraocular" or "implantation" or "blue light filtering" or "blue blocking" or "AcrySof Natural" or "SN60AT" or "yellow intraocular lens" or "YA60BB". In addition, the reference lists of potentially relevant manuscripts were scanned backwards to obtain extra eligible studies. No language restrictions were applied.

2. Inclusion criteria {#s2b}
---------------------

**2.1. Type of study:** For inclusion, studies had to be randomized controlled trials (RCTs) comparing postoperative visual performance of blue light-filtering IOLs and UV light-filtering IOLs. Simulation experiments with blue light-filtering IOLs and UV light-filtering IOLs and clinical trials containing aspherical or multifocal IOLs were excluded.

**2.2. Object of study:** Patients with age-related cataract had phacoemulsification and IOL implantation. Otherwise, patients with ocular disease, such as glaucoma or age-related macular degeneration, preexisting systemic disease such as diabetes, or history of intraocular surgery that could affect the postoperative visual outcome were excluded.

**2.3. Interventions:** In addition to the different types of intraocular lens (blue light-filtering IOL or UV light-filtering IOL) implanted in the two groups, the interventions were the same.

**2.4. Outcome measures:** Main outcome measures included postoperative best corrected visual acuity, contrast sensitivity and color vision. Secondary outcome measures included postoperative visual quality assessment and adverse visual events.

3. Data extraction {#s2c}
------------------

Two independent investigators (Zhu and Yu) were involved in data extraction. The third investigator (Zou) examined the results, and a consensus was reached. The outcome in patients at the end of follow-up after phacoemulsification and IOL implantation was reviewed. We extracted the following data from the eligible studies: (1) general characteristics (title, first author, journal and year of publication); (2) methodology (type of study, country of origin, sequence generation, allocation concealment, masking or blinding, incomplete outcome data, selective reporting and other sources of bias); (3) subjects (recruitment site, enrollment periods, inclusion criteria, exclusion criteria, general patient characteristics); (4) Interventions and control groups (model of IOLs); (5) outcomes (measurement, follow-up time and loss of follow-up); (6) analysis (statistical methods); (7) results (quantitative results, qualitative results, postoperative visual quality assessment and adverse visual events). If original data were unavailable in articles, a request for original data was sent to the corresponding author.

4. Assessment of methodology quality {#s2d}
------------------------------------

Two independent investigators (Zhu and Yu) evaluated the quality of each study using the Jadad scale [@pone.0033013-Jadad1]. The third investigator (Zou) examined the results, and a consensus was reached. The Jadad score is obtained from a possible 5-point scale, high scores indicating high quality, by yes/no answers to two questions for randomization and masking, and one question evaluating the reporting of patient withdrawals and dropouts. One point is given for each of the following: if the study is described as randomized, if the study is described as double-blind and if there is a description of withdrawals or dropouts. Two additional points are given if the method of randomization and the method of double blinding are appropriately described.

5. Statistical analysis {#s2e}
-----------------------

The meta-analysis was performed with the Stata version 11.0 (Stata Corp). For continuous data, the weighted mean difference (WMD) and 95%CI were recommended when all trials used the same scale to report their outcomes, while standardized mean difference (SMD) and 95%CI were more appropriate when trials used different scales to report their outcomes, or the means of their outcomes differed greatly. For dichotomous data, rate ratio or relative risk (RR) was strongly recommended for effect statistics for meta-analysis of randomized trials.

Statistical heterogeneity was tested by Q-test (x^2^) [@pone.0033013-Higgins1] for each outcome, with a significance set at a P value\<0.10. Insignificance indicates that the results of the different trials were similar (P≥0.1, I^2^≤50%). We evaluated the pooled summary effect by using a fixed-effect model to reduce the effects of heterogeneity between trials. Otherwise, data were combined using the random-effect model (P\<0.1, I^2^\>50%). If I^2^\>75%, subgroup analysis was used to analysis the sources of heterogeneity. Sensitivity analysis calculated within subgroups of studies decided a priori were performed to assess the robustness of the main conclusions and explain heterogeneity. To determine whether the results of the meta-analysis were unduly influenced by any outcome measures in any one study, we recomputed the meta-analysis statistic after deleting each outcome measure one at a time.

Individual and pooled results were illustrated by point estimates and 95% confidence intervals (CIs). Results where the 95% CI did not include zero (for mean difference) or one (for odds ratio) were considered statistically significant. Where data could not be combined, we conducted a descriptive analysis.

Results {#s3}
=======

1. Literature search {#s3a}
--------------------

A total of 107 abstracts from the multiple databases were retrieved, 68 of which were based on their titles and abstracts. Only 15 randomized controlled trials (RCTs) [@pone.0033013-Hayashi1], [@pone.0033013-Marshall1], [@pone.0033013-Wirtitsch1]--[@pone.0033013-Wang1] recruiting 1690 eyes were included in our analysis. The trials selection process is shown in [Figure 1](#pone-0033013-g001){ref-type="fig"}.

![Process of study selection of RCTs.](pone.0033013.g001){#pone-0033013-g001}

2. Characteristics of eligible studies {#s3b}
--------------------------------------

Characteristics of RCTs included in the current meta-analysis are presented in [Table 1](#pone-0033013-t001){ref-type="table"} and [Table 2](#pone-0033013-t002){ref-type="table"}. More than half of the studies [@pone.0033013-Wirtitsch1], [@pone.0033013-Barisi1], [@pone.0033013-Marshall1], [@pone.0033013-Schmidinger1], [@pone.0033013-Mester1], [@pone.0033013-Vuori1], [@pone.0033013-Caporossi1], [@pone.0033013-Caporossi2], [@pone.0033013-NeumaierAmmerer1] (60%, 9/15) were performed in Europe followed by 4 studies [@pone.0033013-Hayashi1], [@pone.0033013-Bhattacharjee1], [@pone.0033013-Pandita1], [@pone.0033013-Wang1] in Asia; one study [@pone.0033013-Leibovitch1] from Australia and one study [@pone.0033013-Rocha1] from Brazil. The mean age of patients in most of the studies ranged from 50 to 88 years. The mean percentage of female patients ranged from 48.51% to 75%, as shown in [Table 1](#pone-0033013-t001){ref-type="table"}. The mean follow-up time ranged from 2 months to 2 years ([Table 2](#pone-0033013-t002){ref-type="table"}).

10.1371/journal.pone.0033013.t001

###### Characteristics of RCTS (n = 15) included in the meta-analysis.

![](pone.0033013.t001){#pone-0033013-t001-1}

  First author (date)                                         Site      No. patients   No. eyes      Age (years)      Sex(%) male: female                Intervention
  -------------------------------------------------------- ----------- -------------- ---------- ------------------- --------------------- ----------------------------------------
  Hayashi 2006 [@pone.0033013-Hayashi1]                       Japan          80          160      71.1±6.7/70.7±6.2       12∶26/12∶24                  YA-60BB/VA-60BB
  Wirtitsch 2009 [@pone.0033013-Wirtitsch1]                  Austria         24           48            74±8                 6∶18                      YA-60BB/VA-60BB
  Barisić 2007 [@pone.0033013-Barisi1]                       Croatia         60          120        68±4.5/67±4.2          9∶21/9∶21        Acrysof Natural IOL/AcrySof MA60BM IOL
  Marshall 2005 [@pone.0033013-Marshall1]                    England        297          594        ≥60 (0.3/1.0)     29.3∶70.7/39.5∶60.5               SN60AT/SA60AT
  Bhattacharjee 2006 [@pone.0033013-Bhattacharjee1]           India          13           26         62.15±6.68             6∶7/6∶7                     SN60AT/SA60AT
  Schmidinger 2008 [@pone.0033013-Schmidinger1]              Austria         31           62         73.40±7.64               NA                       YA-60BB/VA-60BB
  Mester 2008 [@pone.0033013-Mester1]                        Germany         47           94        Range 50--80              NA                       YA-60BB/VA-60BB
  Leibovitch 2006 [@pone.0033013-Leibovitch1]               Australia        19           19          74±6/74±6             3∶6/6∶4                     SN60AT/SA60AT
  Vuori 2006 [@pone.0033013-Vuori1]                          Finland         37           52          72±8/73±7               NA                        SN60AT/SA60AT
  Rocha 2007 [@pone.0033013-Rocha1]                          Brazil          40           80          71.0/69.2               2∶3                     SN60AT/Sensar AR40
  Caporossi 2009 [@pone.0033013-Caporossi1]                   Italy          50          100      70.2±4.1/68.4±5.1           NA                      SN60AT/Sensar AR40
  Caporossi 2007 [@pone.0033013-Caporossi2]                   Italy          50          100      70.2±4.1/68.4±5.1           NA                      SN60AT/Sensar AR40
  Pandita 2007 [@pone.0033013-Pandita1]                       India          80           80         61±2.7/59±3          51∶49/52∶48                   SN60AT/SA60AT
  Neumaier-Ammerer 2010 [@pone.0033013-NeumaierAmmerer1]     Austria         80           80             NA                   NA               YA-60BB/VA-60BB & SN60AT/SA60AT
  Wang 2010 [@pone.0033013-Wang1]                             China          79           79            67±8                  NA                        YA-60BB/MC611

NA, not available.

10.1371/journal.pone.0033013.t002

###### Characteristics of RCTS (n = 15) included in the meta-analysis.

![](pone.0033013.t002){#pone-0033013-t002-2}

  First author (date)                                       Measurement                                       Follow-up                                                           Loss                                
  -------------------------------------------------------- ------------- ----------------------------------------------------------------------------------- ---------------------------------------------- --------- --------------------
  Hayashi 2006 [@pone.0033013-Hayashi1]                         \*                                           \* CAT-2000                                                           NA                          3 m       6 of 80 (7.5%)
  Wirtitsch 2009 [@pone.0033013-Wirtitsch1]                     \*                                           \* Holladay                                                    \* Lanthony D-15                 90±10 d           No
  Barisić 2007 [@pone.0033013-Barisi1]                          \*                                               NA                                                                NA                          6 m             No
  Marshall 2005 [@pone.0033013-Marshall1]                       \*                                          \* CSV-1000E                                      \* FM[???](#nt105){ref-type="table-fn"} D-15     1 y     86 of 297 (28.96%)
  Bhattacharjee 2006 [@pone.0033013-Bhattacharjee1]             \*                                         \* Pelli-Robson                                                   \* FM 100-hue                    18 m             No
  Schmidinger 2008 [@pone.0033013-Schmidinger1]                 \*                                          \* Moorfields                                                          NA                         12 w      3 of 31 (9.68%)
  Mester 2008 [@pone.0033013-Mester1]                           \*        \* ETDRS[???](#nt103){ref-type="table-fn"}+FACT[???](#nt104){ref-type="table-fn"}                  \* FM 100-hue                    12 m      8 of 47 (17.02%)
  Leibovitch 2006 [@pone.0033013-Leibovitch1]                   \*                                         \* Pelli-Robson                                                     \* FM D-15                      6 m             No
  Vuori 2006 [@pone.0033013-Vuori1]                             \*                                               NA                                                          \* FM 100-hue                     6 m             No
  Rocha 2007 [@pone.0033013-Rocha1]                             \*                                               NA                                                                NA                         90 d      10 of 80 (12.5%)
  Caporossi 2009 [@pone.0033013-Caporossi1]                     \*                                          \* Optec 6500                                                          NA                          2 y       6 of 50 (12%)
  Caporossi 2007 [@pone.0033013-Caporossi2]                     \*                                          \* Optec 6500                                                          NA                          2 m             No
  Pandita 2007 [@pone.0033013-Pandita1]                         \*                                          \* CSV-1000E                                                           NA                          3 m      7 of 80 (8.75%)
  Neumaier-Ammerer 2010 [@pone.0033013-NeumaierAmmerer1]        \*                                   \* CSV-1000E + Pelli-Robson                                             \* Roth 28-hue                    2 m        4 of 80 (5%)
  Wang 2010 [@pone.0033013-Wang1]                               \*                                      \* ETDRS + Optec 6500                                                \* FM 100-hue                     3 m             No

\*, yes; d = days; m = months; y = years; NA, not available.

ETDRS, Early Treatment Diabetic Retinopathy Study contrast charts;

FACT, Functional acuity contrast test;

FM, Farnsworth-Munsell.

3. Quality assessment {#s3c}
---------------------

**3.1. Sequence generation:** In 6 of all the RCTs included in the systematic review, the investigators described a random component in the sequence generation process such as: referring to a random number table [@pone.0033013-Hayashi1] or using a computer random number generator [@pone.0033013-Pandita1] or shuffling envelopes [@pone.0033013-Leibovitch1], [@pone.0033013-Vuori1], [@pone.0033013-NeumaierAmmerer1]. The remainder did not describe the specific methods of random sequence generation.

**3.2. Masking:** Of 13 studies that described their masking or binding, 1 used triple-blinding [@pone.0033013-Pandita1], 8 used double-blinding [@pone.0033013-Hayashi1], [@pone.0033013-Wirtitsch1], [@pone.0033013-Bhattacharjee1]--[@pone.0033013-Mester1], [@pone.0033013-Vuori1], [@pone.0033013-NeumaierAmmerer1], [@pone.0033013-Wang1] and 4 used single-blinding [@pone.0033013-Marshall1], [@pone.0033013-Barisi1], [@pone.0033013-Leibovitch1], [@pone.0033013-Caporossi2].

**3.3. Withdrawals:** All studies described the data of missing patients. Among these, 8 studies had missing cases: 6 of 80 (7.5%) [@pone.0033013-Hayashi1]; 86 of 297 (28.96%) [@pone.0033013-Marshall1]; 3 of 31 (9.68%) [@pone.0033013-Schmidinger1]; 8 of 47 (17.02%) [@pone.0033013-Mester1]; 10 of 80 (12.5%) [@pone.0033013-Rocha1]; 6 of 50 (12%) [@pone.0033013-Caporossi1]; 7 of 80 (8.75%) [@pone.0033013-Pandita1]; and 4 of 80(5%) [@pone.0033013-NeumaierAmmerer1].

**3.4. Other sources of bias:** Only 2 studies used the following or an equivalent method to achieve allocation concealment: sealed envelopes [@pone.0033013-Vuori1] or sequential numbering [@pone.0033013-Hayashi1].

Eight studies [@pone.0033013-Hayashi1], [@pone.0033013-Marshall1], [@pone.0033013-Wirtitsch1]--[@pone.0033013-Bhattacharjee1], [@pone.0033013-Mester1], [@pone.0033013-Leibovitch1], [@pone.0033013-Wang1] described the patients\' subjective satisfaction of visual quality between the blue light-filtering IOL and UV light-filtering IOL after surgery, and the other studies did not. Therefore, we do not know the existence of other potential factors.

The quality assessment of included studies is shown in [Table 3](#pone-0033013-t003){ref-type="table"}.

10.1371/journal.pone.0033013.t003

###### Evaluation of the quality of RCTs included in the meta-analysis.

![](pone.0033013.t003){#pone-0033013-t003-3}

  Study                                                     Sequence generation   Double-blind   Withdrawals   Jadad score(0--5)
  -------------------------------------------------------- --------------------- -------------- ------------- -------------------
  Hayashi 2006 [@pone.0033013-Hayashi1]                          Adequate           Adequate         DS                5
  Wirtitsch 2009 [@pone.0033013-Wirtitsch1]                      Adequate           Adequate         DS                5
  Barisić 2007 [@pone.0033013-Barisi1]                              UA                 SB            DS                2
  Marshall 2005 [@pone.0033013-Marshall1]                           UA                 SB            DS                2
  Bhattacharjee 2006 [@pone.0033013-Bhattacharjee1]                 UA              Adequate         DS                4
  Schmidinger 2008 [@pone.0033013-Schmidinger1]                     UA              Adequate         DS                4
  Mester 2008 [@pone.0033013-Mester1]                               UA              Adequate         DS                4
  Leibovitch 2006 [@pone.0033013-Leibovitch1]                    Adequate              SB            DS                3
  Vuori 2006 [@pone.0033013-Vuori1]                              Adequate           Adequate         DS                5
  Rocha 2007 [@pone.0033013-Rocha1]                                 UA                 NA            DS                2
  Caporossi 2009 [@pone.0033013-Caporossi1]                         UA                 NA            DS                2
  Caporossi 2007 [@pone.0033013-Caporossi2]                         UA                 SB            DS                2
  Pandita 2007 [@pone.0033013-Pandita1]                          Adequate           Adequate         DS                5
  Neumaier-Ammerer 2010 [@pone.0033013-NeumaierAmmerer1]         Adequate              NA            DS                4
  Wang 2010 [@pone.0033013-Wang1]                                   UA              Adequate         DS                4

UA, Unclear; SB, Single blinding; DB, Double blinding; TB, Triple blinding; DS, Described; NA, not available.

4. Efficacy analysis {#s3d}
--------------------

**4.1. Postoperative best corrected visual acuity (BCVA):** All studies described postoperative BCVA; the results of 8 studies [@pone.0033013-Schmidinger1], [@pone.0033013-Mester1], [@pone.0033013-Vuori1]--[@pone.0033013-Pandita1], [@pone.0033013-Wang1] (596 eyes) were LogMAR transformation, including mean (m), standard deviation (SD) and sample size (n). Also, these studies had heterogeneity of effect size (P = 0.0001, I^2^ = 78.3%), so the random effect model was used for meta-analysis. The results are shown in [Figure 2](#pone-0033013-g002){ref-type="fig"}. No significant difference between the two groups \[WMD = −0.01, 95%CI (−0.03, 0.01), P = 0.46\], indicated that blue light-filtering IOL groups and UV light-filtering IOL groups were not significantly different in postoperative BCVA.

![Meta-analysis of postoperative best corrected visual acuity (BCVA).](pone.0033013.g002){#pone-0033013-g002}

Subgroup analysis was conducted at the same time, according to the different IOL types. The studies were divided into four subgroups: blue light-filtering AcrySof Natural SN60AT IOL vs. UV light-filtering Sensar AR40e IOL (Subgroup 1) [@pone.0033013-Rocha1]--[@pone.0033013-Caporossi2]; blue light-filtering Hoya YA60BB vs. UV light-filtering VA60BB (Subgroup 2) [@pone.0033013-Schmidinger1], [@pone.0033013-Mester1]; blue light-filtering AcrySof Natural SN60AT IOL vs. UV light-filtering AcrySof SA60AT IOL (Subgroup 3) [@pone.0033013-Vuori1], [@pone.0033013-Pandita1]; and blue light-filtering Hoya YA60BB vs. UV light-filtering MC61131 (Subgroup 4) [@pone.0033013-Wang1]. The results are shown in [Figure 3](#pone-0033013-g003){ref-type="fig"}.

![Subgroup analysis of postoperative best corrected distance visual acuity (BCVA).](pone.0033013.g003){#pone-0033013-g003}

All four subgroups were used to produce the random effect model for BCVA, and the results obtained from any subgroup show no significant differences. The results are as follows: Subgroup 1 (SN60AT vs. AR40e IOL, three studies [@pone.0033013-Rocha1]--[@pone.0033013-Caporossi2], recruiting 258 eyes) \[WMD = 0.00, 95%CI (−0.01, 0.02), P = 0.763\]; Subgroup 2 (YA60BB vs. VA60BB, two studies [@pone.0033013-Schmidinger1], [@pone.0033013-Mester1], recruiting 134 eyes) \[WMD = −0.01, 95%CI (−0.04, 0.01), P = 0.294\]; Subgroup 3 (SN60AT vs. SA60AT, two studies [@pone.0033013-Vuori1], [@pone.0033013-Pandita1], recruiting 125 eyes) \[WMD = −0.02, 95%CI (−0.06, 0.02), P = 0.27\]; Subgroup 4 (YA60BB vs. MC611, one study [@pone.0033013-Wang1], recruiting 79 eyes) \[WMD = 0.01, 95%CI (−0.01, 0.03), P = 0.42\]. All the results indicated that blue light-filtering IOL groups and UV light-filtering IOL groups were not significantly different in postoperative BCVA.

**4.2. Postoperative contrast sensitivity:** Twelve studies [@pone.0033013-Hayashi1], [@pone.0033013-Marshall1], [@pone.0033013-Wirtitsch1], [@pone.0033013-Bhattacharjee1]--[@pone.0033013-Leibovitch1], [@pone.0033013-Caporossi1]--[@pone.0033013-Wang1] compared the contrast sensitivity of blue light-filtering IOLs and UV light-filtering IOLs after implantation. The methods of assessing contrast sensitivity were described in [Table 2](#pone-0033013-t002){ref-type="table"}. However, most of the literature using several different methods reported only the contrast sensitivity graph or P value, but no detailed data. On the other hand, for part of the data in reports, means and standard deviations cannot be calculated, and there was failure to pool analysis. Although we tried to contact the author, results of the corresponding data were not obtained. Thus, these could cause measurement bias. Thereafter, we conducted a descriptive analysis with results shown in [Table 4](#pone-0033013-t004){ref-type="table"}.

10.1371/journal.pone.0033013.t004

###### Comparison of postoperative contrast sensitivity in two groups.

![](pone.0033013.t004){#pone-0033013-t004-4}

                                                                                                                       Photopic Conditions                                                 Mesopic Conditions                                              
  -------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------------------- ----------------------------------- -----------------------------------
  SN60AT/SA60AT                Marshall 2005 [@pone.0033013-Marshall1]                                                          NA                                                  [\*](#nt107){ref-type="table-fn"}                  NA                   [\*](#nt107){ref-type="table-fn"}
                                Pandita 2007 [@pone.0033013-Pandita1]                                                           NA                                                  [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}
                        Neumaier-Ammerer 2010 [@pone.0033013-NeumaierAmmerer1]                                  [\*](#nt107){ref-type="table-fn"}                                   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}
  SN60AT/Sensar AR40          Caporossi 2009 [@pone.0033013-Caporossi1]                                                         NA                                                  [\*](#nt107){ref-type="table-fn"}                  NA                   [\*](#nt107){ref-type="table-fn"}
                              Caporossi 2009 [@pone.0033013-Caporossi2]                                                         NA                                                  [\*](#nt107){ref-type="table-fn"}                  NA                   [\*](#nt107){ref-type="table-fn"}
                                Hayashi 2006 [@pone.0033013-Hayashi1]                                           [\*](#nt107){ref-type="table-fn"}                                   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}
                              Wirtitsch 2009 [@pone.0033013-Wirtitsch1]          The blue light-filtering IOLs had worse contrast sensitibity compared with the UV-filtering IOL.                                                                          
  YA-60BB/VA-60BB           Schmidinger 2008 [@pone.0033013-Schmidinger1]                                                       NA                                                  [\*](#nt107){ref-type="table-fn"}                  NA                                  NA
                                 Mester 2008 [@pone.0033013-Mester1]                                                            NA                                                  [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}
                        Neumaier-Ammerer 2010 [@pone.0033013-NeumaierAmmerer1]                                  [\*](#nt107){ref-type="table-fn"}                                   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}
  YA-60BB/MC611                    Wang 2010 [@pone.0033013-Wang1]                                              [\*](#nt107){ref-type="table-fn"}                                   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}   [\*](#nt107){ref-type="table-fn"}

, No statistically significant difference; NA, not available.

Only two studies [@pone.0033013-Bhattacharjee1], [@pone.0033013-Leibovitch1] recruiting 45 eyes used the same measurement method (Pelli-Robson contrast sensitivity chart), and reported complete data. They had no heterogeneity of effect size (P = 0.609, I^2^ = 0%), so the fixed effect model was used for meta-analysis. No significant difference between the two groups was seen \[WMD = 0.07, 95%CI (−0.04, 0.19), P = 0.20\], indicating that blue light-filtering IOL groups and UV light-filtering IOL groups were not significantly different in postoperative contrast sensitivity. The results are shown in [Figure 4](#pone-0033013-g004){ref-type="fig"}.

![Meta-analysis of postoperative contrast sensitivity.](pone.0033013.g004){#pone-0033013-g004}

**4.3. Postoperative color vision:** Eight studies [@pone.0033013-Marshall1], [@pone.0033013-Wirtitsch1], [@pone.0033013-Bhattacharjee1], [@pone.0033013-Mester1]--[@pone.0033013-Vuori1], [@pone.0033013-NeumaierAmmerer1], [@pone.0033013-Wang1] compared the color vision of blue light-filtering IOLs and UV light-filtering IOLs after implantation. The methods of assessing color vision were described in [Table 2](#pone-0033013-t002){ref-type="table"}. Five of them [@pone.0033013-Mester1]--[@pone.0033013-Vuori1], [@pone.0033013-NeumaierAmmerer1], [@pone.0033013-Wang1] reported complete data, and one [@pone.0033013-Mester1] reported that color vision for blue with the blue light-filtering IOL was significantly reduced under photopic and mesopic conditions; another study [@pone.0033013-Wang1] reported that the UV light-filtering IOL had significantly better color vision than the blue light-filtering IOL under mesopic conditions. The remaining studies showed no statistically significant difference.

Two studies [@pone.0033013-Leibovitch1], [@pone.0033013-Vuori1] recruiting 71 eyes used different scales to report their outcomes in overall color vision, so that standardized mean differences (SMD) were more appropriate. They also had no heterogeneity of effect size (P = 0.59, I^2^ = 0%), so the fixed effect model was used for meta-analysis. No significant difference between the two groups was seen \[SMD = 0.14, 95%CI (−0.33, 0.60), P = 0.566\], indicating that blue light-filtering IOL groups and UV light-filtering IOL groups were not significantly different in postoperative color vision. The results are shown in [Figure 5](#pone-0033013-g005){ref-type="fig"}.

![Meta-analysis of postoperative overall color vision.](pone.0033013.g005){#pone-0033013-g005}

Four studies [@pone.0033013-Mester1], [@pone.0033013-Vuori1], [@pone.0033013-NeumaierAmmerer1], [@pone.0033013-Wang1] recruiting 281 eyes tested postoperative color vision in the blue light spectrum under photopic light conditions. They used different scales to report their outcomes, so standardized mean differences (SMD) were more appropriate. Also, they had no heterogeneity of effect size (P = 0.806, I^2^ = 0%), so the fixed effect model was used for meta-analysis. No significant differences were seen between the two groups \[SMD = 0.20, 95%CI (−0.04, 0.43), P = 0.099\], indicating that blue light-filtering IOL groups and UV light-filtering IOL groups were not significantly different in postoperative color vision in the blue light spectrum under photopic light conditions. The results are shown in [Figure 6](#pone-0033013-g006){ref-type="fig"}.

![Meta-analysis of postoperative color vision in the blue light spectrum under photopic light condition.](pone.0033013.g006){#pone-0033013-g006}

In addition, a sensitivity analysis suggested that the result was stable after deleting anyone\'s particular outcome. The results are shown in [Figure 7](#pone-0033013-g007){ref-type="fig"}.

![Sensitivity analysis of postoperative color vision in the blue light spectrum under photopic light condition.](pone.0033013.g007){#pone-0033013-g007}

Three studies [@pone.0033013-Mester1], [@pone.0033013-NeumaierAmmerer1], [@pone.0033013-Wang1] recruiting 229 eyes tested postoperative color vision in the blue light spectrum under mesopic light conditions. They used different scales to report their outcomes, so standardized mean differences (SMD) were more appropriate. Also, they had no heterogeneity of effect size (P = 0.05, I^2^ = 61.7%), so the random effect model was used for meta-analysis. There was a significant difference between the two groups \[SMD = 0.74, 95%CI (0.29, 1.18), P = 0.001\], indicating that color vision for blue with blue light-filtering IOLs was significantly reduced under mesopic conditions. The results are shown in [Figure 8](#pone-0033013-g008){ref-type="fig"}.

![Meta-analysis of postoperative color vision in the blue light spectrum under mesopic light condition.](pone.0033013.g008){#pone-0033013-g008}

Additionally, the sensitivity analysis revealed that color vision with blue light-filtering IOLs was significantly reduced under mesopic conditions in the blue light spectrum. The results are shown in [Figure 9](#pone-0033013-g009){ref-type="fig"}.

![Sensitivity analysis of postoperative color vision in the blue light spectrum under mesopic light condition.](pone.0033013.g009){#pone-0033013-g009}

**4.4. Postoperative subjective satisfaction of visual quality and adverse visual events:** Four studies [@pone.0033013-Hayashi1], [@pone.0033013-Wirtitsch1], [@pone.0033013-Barisi1], [@pone.0033013-Schmidinger1] reported that different patients\' subjective satisfaction of visual quality between the blue light-filtering IOL and UV light-filtering IOL after surgery. In the two studies [@pone.0033013-Hayashi1], [@pone.0033013-Wirtitsch1] that used questionnaires for evaluation, Wirtitsch and associates [@pone.0033013-Wirtitsch1] using a questionnaire regarding color vision or contrast vision or vision under poor light conditions, they reported that 3 of 24 patients noticed a difference and all could correctly identify the eye implanted with the blue light-filtering IOL. However, all 3 patients said that they were not disturbed in binocular vision. In the report by Hayashi and associates [@pone.0033013-Hayashi1], where patients were given a standardized questionnaire regarding glare symptoms and cyanopsia, the authors found that the incidence of patients who noticed cyanopsia was significantly less in the blue light-filtering IOL group than in the UV light-filtering IOL group at 2 weeks after surgery (p = 0.0234), but no patients reported cyanopsia at 3 months. In addition, another two studies [@pone.0033013-Barisi1], [@pone.0033013-Schmidinger1] reported different patients\' subjective satisfaction and subjective color vision in the left eye and right eye. Barisić and associates [@pone.0033013-Barisi1] described high satisfaction in patients who were implanted with a blue light-filtering IOL. Schmidinger and associates [@pone.0033013-Schmidinger1] found that 2 patients independently reported subjective changes in color vision in the eye with the blue light-filtering IOL; the changes probably resulted from the difference in color brightness because yellow IOLs reduce color brightness in the blue range of visible light. Furthermore, four studies [@pone.0033013-Marshall1], [@pone.0033013-Mester1], [@pone.0033013-Leibovitch1], [@pone.0033013-Wang1] found no significant differences in subjective satisfaction of visual quality or lens-related adverse events in either group after surgery, which only Wang and associates [@pone.0033013-Wang1] used the standardized questionnaire regarding subjective evaluation of glare, halo, and color vision perception. The remaining studies reported no relevant results in this regard.

Discussion {#s4}
==========

This systematic review compared the postoperative visual performance of RCTs between blue light-filtering IOLs and UV light-filtering IOLs, with the results showing that no statistically significant differences were found in comparing postoperative best corrected visual acuity, contrast sensitivity, and overall color vision. However, blue light-filtering IOLs demonstrated some compromise in the blue light spectrum under mesopic light conditions.

Large-scale epidemiological and animal studies have demonstrated that exposure to short wavelength visible light may be associated with a potential risk for accelerating the pathology of age-related macular degeneration (AMD) and retinal damage [@pone.0033013-Ham1], [@pone.0033013-Tomany1], [@pone.0033013-Cruickshanks1]--[@pone.0033013-Hafezi1]. The natural aging crystalline lens can absorb amounts of UV and visible light, due to natural yellowing and opacification, going against the phototoxicity-AMD hypothesis [@pone.0033013-vanNorren1]. Evidence suggests that blue light can damage the macula in patients who have undergone cataract surgery or clear lens extraction [@pone.0033013-Cugati1]. Therefore, an ideal IOL should be similar to that of the adult crystalline lens. Blue light-filtering IOLs show transmittance curves similar to that of a 53-year-old person\'s natural crystalline lens to help reduce the potential damage from blue light reaching the retina [@pone.0033013-Brockmann1].

The implantation of blue light-filtering IOLs caused debate over their potential negative effects on postoperative visual performance, such as BCVA, contrast sensitivity and color vision, especially in dark conditions. We found that most of the literature overwhelmingly demonstrated that there were no detrimental effects of blue light-filtering IOLs on clinical visual recovery, which was consistent with our results. However, Mester and associates [@pone.0033013-Mester1], in one of the included studies, mentioned that color vision in the blue light spectrum with the blue light-filtering IOLs (HOYA YA60BB) was significantly reduced under mesopic and photopic conditions: the impairment did not exceed the normal range or induce subjective disturbance of color vision. Furthermore, Barisić and associates [@pone.0033013-Barisi1] indicated that the blue light-filtering IOLs (HOYA YA60BB) had inferior contrast acuity and foveal threshold compared with the UV light-filtering IOLs. Unfortunately, we could not obtain complete data for a pooled analysis. Wang and associates [@pone.0033013-Wang1] reported that blue light-filtering IOLs gave poor contrast sensitivity and color vision under mesopic conditions, which was in agreement with the conclusions of Neumaier-Ammerer and associates [@pone.0033013-NeumaierAmmerer1]. In fact, blue light-filtering IOLs have been shown to reduce the incidence of photophobia and cyanopsia in the early postoperative period [@pone.0033013-Yuan1], [@pone.0033013-Yap1].

Meta-analysis is the pooling of data from a number of different studies and objectively reanalyzing the resulting data set to provide a more precise result to assist in making clinical decisions. A possible limitation includes inappropriate pooling of data and publication bias. In our analysis, to avoid acknowledged and unintended duplication of data, we included only the most recent series of patient groups and randomized controlled trials, which are the optimal choice for meta-analyses. To minimize the publication bias, we conducted an electronic search and a manual search of the references of relevant studies to identify all the potential articles. This systematic review included 15 studies, all of which met the strict inclusion criteria; therefore, the intervention groups and control groups were comparable. However, the overall quality of the studies was not high. Only six studies had adequate sequence generation, two studies used adequate methods to achieve allocation concealment, and 2 studies made no mention of masking. In addition, different follow-up times and less reporting of postoperative visual adverse events could cause selection bias. Several studies lacked sufficient data for analysis, or involved different measurement methods, or used different units of measurement, or not used a standard questionnaire to assess: all of these could cause measurement bias. All the information in this systematic review came from the published literature, with special reports or unpublished data not being included, as they could cause publication bias. Therefore, to improve the quality of RCTs in the future, further verification of the postoperative visual performance and safety of blue light-filtering IOLs is needed. The format of reports should comply with the rules of CONSORT, providing detailed and transparent information in order to judge the authenticity of the outcomes.

In conclusion, our systematic review, as well as other clinical reports, suggests that the blue light-filtering IOLs had postoperative visual performance comparable to the UV light-filtering IOLs, but conclusions regarding color vision are still inconsistent.

**Competing Interests:**The authors have declared that no competing interests exist.

**Funding:**No current external funding sources for this study.

[^1]: Conceived and designed the experiments: HZ XZ. Performed the experiments: XZ HZ QS YY. Analyzed the data: HZ XZ YY NZ. Contributed reagents/materials/analysis tools: HZ XZ YZ. Wrote the paper: XZ HZ.
